Establishing evidence for change in ovarian cancer surgery - Proposing clinical trials of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer peritoneal carcinomatosis

Gynecologic Oncology

Volumn 115, Issue 1, 2009, Pages 166-168

  Chua, Terence C ^a   Liauw, Winston ^b   Robertson, Greg ^b   Morris, David L ^a,c  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b ST GEORGE HOSPITAL   (Australia)

^c KING FAHAD MEDICAL CITY   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN;

ALGORITHM; CARCINOMATOUS PERITONITIS; CLINICAL RESEARCH; CYTOREDUCTIVE SURGERY; HUMAN; HYPERTHERMIC THERAPY; LETTER; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL;

COMBINED MODALITY THERAPY; FEMALE; HUMANS; HYPERTHERMIA, INDUCED; INFUSIONS, PARENTERAL; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 69249221317     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2009.06.010     Document Type: Letter

References (20)

1. Chua T.C., Liauw W., Robertson G., Chia W.K., Soo K.C., Alobaid A., et al. Towards randomized trials of peritonectomy and hyperthermic intraperitoneal chemotherapy for ovarian cancer peritoneal carcinomatosis. Gynecol. Oncol. (2009) Electronic publication
2. Yan T.D., Welch L., Black D., and Sugarbaker P.H. A systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignancy peritoneal mesothelioma. Ann. Oncol. 18 (2007) 827-834
3. Yan T.D., Black D., Savady R., and Sugarbaker P.H. A systematic review on the efficacy of cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei. Ann. Surg. Oncol. 14 (2007) 484-492
4. Yan T.D., Black D., Savady R., and Sugarbaker P.H. Systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal carcinoma. J. Clin. Oncol. 24 (2006) 4011-4019
5. Chua TC, Yan TD, Saxena A, Morris DL. Should the treatment of peritoneal carcinomatosis by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still be regarded as a highly morbid procedure? a multi-institutional review of morbidity and mortality. Ann Surg 2009;249(6):900-7.
6. Eisenkop S.M., Nalick R.H., Wang H.J., and Teng N.N. Peritoneal implant elimination during cytoreductive surgery for ovarian cancer: impact on survival. Gynecol. Oncol. 51 (1993) 224-229
7. Eisenkop S.M., Spirtos N.M., Friedman R.L., Lin W.C., Pisani A.L., and Perticucci S. Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study. Gynecol. Oncol. 90 (2003) 390-396
8. Eisenkop S.M., Friedman R.L., and Wang H.J. Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study. Gynecol. Oncol. 69 (1998) 103-108
9. Eisenkop S.M., and Spirtos N.M. Procedures required to accomplish complete cytoreduction of ovarian cancer: is there a correlation with "biological aggressiveness" and survival?. Gynecol. Oncol. 82 (2001) 435-441
10. Hacker N.F., Berek J.S., Lagasse L.D., Nieberg R.K., and Elashoff R.M. Primary cytoreductive surgery for ovarian cancer. Obstet. Gynecol. 61 (1983) 413-420
11. Covens A.L. A critique of surgical cytoreduction in advanced ovarian cancer. Gynecol. Oncol. 78 (2000) 269-274
12. Alberts D.S., Liu P.Y., Hannigan E.V., O'Toole R., Williams S.D., Young J.A., et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N. Engl. J. Med. 335 (1996) 1950-1955
13. Armstrong D.K., Bundy B., Wenzel L., Huang H.Q., Baergen R., Lele S., et al. The Gynecologic Oncology G. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N. Engl. J. Med. 354 (2006) 34-43
14. Chi D.S., Eisenhauer E.L., Zivanovic O., Sonoda Y., Abu-Rustum N.R., Levine D.A., et al. Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. Gynecol. Oncol. (2009) Electronic publication
15. Bristow R.E., Puri I., and Chi D.S. Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis. Gynecol. Oncol. 112 (2009) 265-274
16. Bristow R.E., Tomacruz R.S., Armstrong D.K., Trimble E.L., and Montz F.J. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J. Clin. Oncol. 20 (2002) 1248-1259
17. Bereder J.M. HIPEC in ovarian cancer - French experience. 6th Workshop on Peritoneal Surface Oncology. Lyon (2008)
18. Di Giorgio A., Naticchioni E., Biacchi D., Sibio S., Accarpio F., Rocco M., et al. Cytoreductive surgery (peritonectomy procedures) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of diffuse peritoneal carcinomatosis from ovarian cancer. Cancer 113 (2008) 315-325
19. Bae J.H., Lee J.M., Ryu K.S., Lee Y.S., Park Y.G., Hur S.Y., et al. Treatment of ovarian cancer with paclitaxel- or carboplatin-based intraperitoneal hyperthermic chemotherapy during secondary surgery. Gynecol. Oncol. 106 (2007) 193-200
20. Ryu K.S., Kim J.H., Ko H.S., Kim J.W., Ahn W.S., Park Y.G., Kim S.J., and Lee J.M. Effects of intraperitoneal hyperthermic chemotherapy in ovarian cancer. Gynecol. Oncol. 94 (2004) 325-332